BioMarin Pharmaceutical Inc. Files 8-K for Regulation FD Disclosure
Ticker: BMRN · Form: 8-K · Filed: Sep 24, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 B, $4 billion, $1.25 billion, $5 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: BMRN
TL;DR
BioMarin dropped an 8-K for a Reg FD disclosure - check for updates.
AI Summary
On September 24, 2024, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure, indicating that the company is releasing material non-public information to the public. No specific financial figures or new business developments were detailed in the provided excerpt.
Why It Matters
This filing signals that BioMarin is making a public announcement of information that could impact investors, ensuring fair disclosure to all market participants.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- September 24, 2024 (date) — Date of Report
- Regulation FD (regulation) — Disclosure Type
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not specify the content of the Regulation FD disclosure; it only indicates that such a disclosure is being made.
When was this 8-K filing submitted?
The 8-K filing was submitted on September 24, 2024.
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure.
What is BioMarin Pharmaceutical Inc.'s principal executive office address?
BioMarin Pharmaceutical Inc.'s principal executive office is located at 770 Lindaro Street, San Rafael, California, 94901.
What is BioMarin's IRS Employer Identification Number?
BioMarin Pharmaceutical Inc.'s IRS Employer Identification Number is 68-0397820.
Filing Stats: 1,213 words · 5 min read · ~4 pages · Grade level 16.3 · Accepted 2024-09-24 08:31:31
Key Financial Figures
- $0.001 B — ich registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market I
- $4 billion — icipates the following: approximately $4 billion in total revenues in 2027; 40% Non-GA
- $1.25 billion — to mid-40% range over time; more than $1.25 billion operating cash flow per year starting i
- $5 billion — conditions to represent a greater than $5 billion revenue opportunity over time. Forwar
Filing Documents
- d887671d8k.htm (8-K) — 33KB
- 0001193125-24-224139.txt ( ) — 150KB
- bmrn-20240924.xsd (EX-101.SCH) — 3KB
- bmrn-20240924_lab.xml (EX-101.LAB) — 17KB
- bmrn-20240924_pre.xml (EX-101.PRE) — 11KB
- d887671d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This current report on Form 8-K contains forward-looking statements about the business prospects of the Company, including, without limitation, statements regarding the Company's future financial performance, including the expectations of Total Revenues, Non-GAAP Operating Margin percentage, Operating Cash Flow and Revenue Compound Annual Growth Rate (CAGR); and the size of the revenue opportunity for potential treatments for skeletal conditions. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others, those factors detailed in BioMarin's Investor Day presentation and press release issued September 4, 2024 and BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as such factors may be updated by any subsequent reports. You should carefully consider that information before you make an investment decision. You should not place undue reliance on forward-looking statements, which speak only as of the date hereof. These forward-looking statements are based on the beliefs and assumptions of the Company's management based on information currently available to management and should be considered in connection with any written or oral forward-looking statements that the Company may issue in the future as well as other cautionary statements the Company has made and may make. Except as required by law, BioMarin does not undertake any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise. Non-GAAP Information The guidance included in this Form 8-K includes both GAAP information and Non-GAAP information. Non-GAAP Operating Margin percentage is defin
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: September 24, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer